Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 7 April 1978:
Vol. 200. no. 4337, pp. 52 - 54
DOI: 10.1126/science.345441
Prev | Table of Contents | Next

Articles

Science, Vol 200, Issue 4337, 52-54
Copyright © 1978 by American Association for the Advancement of Science

articles

Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia

AM Lefer, ML Ogletree, JB Smith, MJ Silver, KC Nicolaou, WE Barnette, and GP Gasic

Prostacyclin, a potent, naturally occurring prostaglandin exerts a variety of cardiovascular and cellular actions of potential value in acute myocardial ischemia. These properties include the reduction of systemic blood pressure without changing heart rate, the lowering of coronary vascular and total peripheral resistance, the inhibition of platelet aggregation and the concomitant formation of thromboxane B2, and the reduction of the release of lysosomal enzymes.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor.
K. Shinmura, K. Tamaki, T. Sato, H. Ishida, and R. Bolli (2005)
Am J Physiol Heart Circ Physiol 288, H2093-H2101
   Abstract »    Full Text »    PDF »
Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling.
R. H. Ritchie, A. C. Rosenkranz, L. P. Huynh, T. Stephenson, D. M. Kaye, and G. J. Dusting (2004)
Am J Physiol Heart Circ Physiol 287, H1179-H1185
   Abstract »    Full Text »    PDF »
Effects of Acetaminophen on Myocardial Infarct Size in Rats.
W. Dai and R. A. Kloner (2003)
Journal of Cardiovascular Pharmacology and Therapeutics 8, 277-284
   Abstract »    PDF »
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial.
D. B. Badesch, V. F. Tapson, M. D. McGoon, B. H. Brundage, L. J. Rubin, F. M. Wigley, S. Rich, R. J. Barst, P. S. Barrett, K. M. Kral, et al. (2000)
Ann Intern Med 132, 425-434
   Abstract »    Full Text »    PDF »
"Myocardial stunning": remaining questions.
D. J Duncker, R. Schulz, R. Ferrari, D. Garcia-Dorado, C. Guarnieri, G. Heusch, and P. D Verdouw (1998)
Cardiovasc Res 38, 549-558
   Full Text »    PDF »
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension.
R. J. Barst, L. J. Rubin, W. A. Long, M. D. McGoon, S. Rich, D. B. Badesch, B. M. Groves, V. F. Tapson, R. C. Bourge, B. H. Brundage, et al. (1996)
N. Engl. J. Med. 334, 296-301
   Abstract »    Full Text »    PDF »
Role of Neutrophils in Myocardial Ischemia and Reperfusion.
P. R. Hansen (1995)
Circulation 91, 1872-1885
   Abstract »    Full Text »
Beneficial Effect of a New Prostacyclin Derivative on the Walking Capacity in Patients with Peripheral Arterial Insufficiency.
G. Brevetti, A. Rossini, S. Perna, A. Policicchio, T. Attisano, M. Ciotola, S. Quattrin, M. Condorelli, and M. Chiariello (1989)
Angiology 40, 907-913
   Abstract »    PDF »
Reduced Myocardial Neutrophil Accumulation and Infarct Size Following Thromboxane Synthetase Inhibitor or Receptor Antagonist.
W. W. Nichols, J. Mehta, T. J. Wargovich, D. Franzini, and D. Lawson (1989)
Angiology 40, 209-221
   Abstract »    PDF »
Status of Antiplatelet Drugs in Coronary Heart Disease.
J. Mehta and P. Mehta (1979)
JAMA 241, 2649-2651
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)